TABLE 6

Experimental vs. clinical anthracycline doses associated with 5% or 1% to 2% HF risk

Clinical values were obtained or extrapolated from von Hoff et al. (1977), Anderlini et al. (1995), Ryberg et al. (1998), Swain et al. (2003), and Winthrop Pharmaceuticals (2010). Bracketed value indicates risk dose percentage decrements induced by CBR polymorphism. Missing data denote a lack of firmly established clinical doses.

HF Risk	CBR Polymorphism	DOX		EPI		DNR		IDA
HF Risk	CBR Polymorphism	Experimental	Clinical	Experimental	Clinical	Experimental	Clinical	Experimental	Clinical
5%	−	380	400	920	900	360	600–800	180	290
	+	330	—	840	—	190	—	105	—
		(−13%)		(−9%)		(−47%)		(−42%)
1%–2%	−	220–280	300–340	580–720	600–700	170–270	—	100–130	—
	+	180–230	—	510–650	—	120–160	—	65–80	—
		(−18%) (−18%)		(−12%) (−10%)		(−29%) (−41%)		(−35%) (−38%)